文献速递细胞病理与分子病理乳腺病理

SOX10/角蛋白双色免疫组化:FNA与小活检上皮样恶性肿瘤一线检测

SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens.
PubMed 文献 · Cancer Cytopathol · 2018-01-31

该研究纳入107例FNA细胞块和小活检标本(黑色素瘤34例、上皮样/多形性肉瘤31例、癌42例),评估SOX10/广谱角蛋白双色免疫组化的鉴别价值。结果显示三种主要染色模式可区分黑色素瘤、肉瘤和癌,提示该双色检测可作为上皮样恶性肿瘤的一线检测方法。

要点

  • SOX10/角蛋白双色IHC可区分黑色素瘤、肉瘤和癌三种上皮样恶性肿瘤。
  • 黑色素瘤呈核SOX10阳性,灵敏度94%、特异度95%。
  • 该检测可减少所需标志物数量,节省组织用于后续治疗相关检测。

核心结论

  • SOX10/角蛋白双色免疫组化是区分黑色素瘤、肉瘤和癌的有效、敏感且特异的检测方法。

研究设计与样本

  • 回顾性纳入107例FNA细胞块(49例)和小活检(58例)标本,包括黑色素瘤34例、上皮样/多形性肉瘤31例、癌42例。
  • 所有标本行双色免疫组化:SOX10用过氧化物酶基棕色显色剂,角蛋白AE1/AE3用碱性磷酸酶基红色显色剂,对病变细胞染色存在与否进行评分。

主要发现

  • 多数肿瘤呈现三种模式之一:黑色素瘤核SOX10阳性(灵敏度94%、特异度95%)。
  • 上皮样/多形性肉瘤SOX10和AE1/AE3均阴性(灵敏度84%、特异度88%)。
  • 癌胞质AE1/AE3阳性(灵敏度76%、特异度98%)。
  • 部分癌(尤其三阴性乳腺癌)呈胞质AE1/AE3阳性伴核SOX10阳性的第四种模式。

临床怎么用

  • 可将SOX10/角蛋白双色IHC作为上皮样恶性肿瘤的一线检测,优先识别黑色素瘤并指导后续标志物选择。
  • 该策略可减少所需标志物数量,节省有限组织用于基因分型等辅助检测,并可能降低费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The characterization of poorly differentiated neoplasms in fine-needle aspiration (FNA) and small biopsy specimens usually requires immunohistochemistry (IHC) with a panel of markers. Because of an increasing need to preserve limited diagnostic material for tumor genotyping and a mounting demand for cost containment, the authors investigated the usefulness of dual-color IHC with antibodies directed against broad-spectrum keratins and SOX10, a neuroectodermal transcription factor consistently expressed in melanoma, in the workup of epithelioid malignant neoplasms. METHODS: A total of 107 cases of FNA cell blocks (49 cases) and small biopsies (58 cases) were selected, including 34 melanomas, 31 epithelioid/pleomorphic sarcomas, and 42 carcinomas. IHC was performed on all specimens using a peroxidase-based brown chromogen for SOX10 and an alkaline phosphatase-based red chromogen for keratins AE1/AE3. The presence or absence of staining in lesional cells was scored. RESULTS: The majority of tumors demonstrated 1 of 3 distinct patterns: 1) malignant melanomas with nuclear SOX10 (sensitivity of 94% and specificity of 95%); 2) epithelioid/pleomorphic sarcomas negative for both SOX10 and AE1/AE3 (sensitivity of 84% and specificity of 88%); and 3) carcinomas with cytoplasmic AE1/AE3 (sensitivity of 76% and specificity of 98%). In addition, a fourth pattern with cytoplasmic AE1/AE3 and nuclear SOX10 was observed in a subset of carcinomas, most notably triple-negative breast cancers. CONCLUSIONS: SOX10/keratin dual-color IHC appears to be an effective, sensitive, and specific test to distinguish between melanoma, sarcoma, and carcinoma. This approach can identify melanoma, prioritize additional studies, and limit the number of markers needed to workup an epithelioid malignant neoplasm, thereby potentially reducing costs and preserving valuable tissue for ancillary studies with which to guide therapy. Cancer Cytopathol 2018;126:179-89. © 2018 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Mito JK, Conner JR, Hornick JL, et al. SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens. Cancer Cytopathol. 2018. PMID: 29385322. doi:10.1002/cncy.21960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。